A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers-Reference-Cited by-同舟云学术

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Published:2017-10-24 Issue:9 Volume:24 Page:2050-2059
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Banerji Udai,Dean Emma J.,Pérez-Fidalgo J. Alejandro,Batist Gerald,Bedard Philippe L.,You Benoit,Westin Shannon N.,Kabos Peter,Garrett Michelle D.,Tall Mathew,Ambrose Helen,Barrett J. Carl,Carr T. Hedley,Cheung S.Y. Amy,Corcoran Claire,Cullberg Marie,Davies Barry R.,de Bruin Elza C.,Elvin Paul,Foxley Andrew,Lawrence Peter,Lindemann Justin P.O.,Maudsley Rhiannon,Pass Martin,Rowlands Vicky,Rugman Paul,Schiavon Gaia,Yates James,Schellens Jan H.M.

Funder

AstraZeneca

CRUKECMCNIHRECMCNIHR

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

2. US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations;Journal of Clinical Oncology;2024-08-19

3. mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors;Cancer Research Communications;2024-08-01

4. Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours;Clinical Pharmacokinetics;2024-08

5. Capivasertib in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative advanced breast cancer;Current Problems in Cancer;2024-08